Danaher Nears $10 Billion Deal to Buy Med-Tech Firm Masimo: FT

Danaher is reportedly on the verge of a $10 billion acquisition of Masimo, a leading medical technology company. This potential deal signals a major move in the healthcare tech industry, combining Danaher’s global reach and innovation capabilities with Masimo’s cutting-edge patient monitoring technology.

What’s the News

• Danaher nears $9.9B acquisition of Masimo: The deal values Masimo at nearly $10 billion, above its recent ~$7 billion market cap.
• Announcement could come soon: Sources say confirmation may arrive this week if talks finalize.
• No official statement yet: Neither Danaher nor Masimo has formally confirmed the transaction.

Who Is Danaher

• Global life sciences leader: Danaher operates in diagnostics, biotech tools, and environmental solutions worldwide.
• Acquisition-driven growth model: The company regularly buys high-growth science and tech firms to expand its portfolio.
• Major past deal in 2020: Danaher acquired Cytiva for $21B, strengthening its bioprocessing business.

Who Is Masimo

• Medical monitoring innovator: Masimo develops advanced noninvasive patient monitoring devices used in hospitals globally.
• Known for pulse oximetry tech: Its SET® technology measures blood oxygen levels without needles.
• Healthcare-focused partnerships: Masimo integrates its sensors into broader clinical systems.

Deal Details

• Deal value around $9.9B: Represents a premium over Masimo’s recent valuation.
• Largest Danaher deal since 2020: Would be its biggest acquisition after the $21B Cytiva buyout.
• Strategic healthcare expansion: Adds high-value patient monitoring to Danaher’s core portfolio.

Why It Matters

• Expands into clinical monitoring: Danaher strengthens presence beyond lab tools into bedside care.
• Stable demand sector: Patient monitoring is essential in hospitals, ICUs, and home healthcare.
• Long-term healthcare growth: Aging populations and chronic diseases drive sustained demand.

Masimo’s Recent Challenges

• $634M Apple patent ruling: A U.S. jury ordered Apple to pay Masimo over pulse oximetry patents; appeal expected.
• Consumer audio diversification setback: Masimo bought Sound United brands, later sold to Samsung’s Harman for ~$350M.
• Leadership disputes occurred: Proxy battles led to management changes in recent years.

Strategic Rationale for Danaher

• Complements diagnostics business: Masimo’s monitoring tech fits Danaher’s healthcare ecosystem.
• Revenue mix improvement: Adds recurring hospital-based device sales.
• Integration potential: Sensor technology could combine with Danaher’s existing platforms.

Market & Financial Impact

• Masimo stock volatility: Shares declined from previous highs amid legal and operational pressures.
• Potential revenue boost for Danaher: Expands into steady clinical revenue streams.
• Investor focus on margins: Analysts will watch integration costs and growth impact.

Regulatory & Integration Risks

• Antitrust review expected: Regulators may examine competition impact in patient monitoring markets.
• Execution risk remains: Large-scale integration requires cultural and operational alignment.
• Track record supports confidence: Danaher successfully integrated Cytiva and Abcam previously.

What’s Next

• Official confirmation awaited: Markets expect a formal announcement soon.
• Regulatory filings to follow: Approval process may take several months.
• Stock reaction closely watched: Investors will monitor price movement and analyst upgrades.

Conclusion

The potential Danaher‑Masimo deal marks a major shift in the healthcare technology world. By moving nearly $10 billion to acquire cutting‑edge patient monitoring tech, Danaher would extend its reach into areas critical for modern clinical care. For Masimo, the acquisition could mean broader distribution and resources to develop the next generation of monitoring solutions.

FAQS

 Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.